Answers are grounded in this paper and cite their sources.
To investigate the association of interleukin-37 (IL-37)(rs3811047) polymorphism with lupus nephritis (LN) in systemic lupus erythematosus (SLE) patients. The case-control study included 206 SLE patients, 97 with LN and 109 without LN, and 240 healthy controls. SLE disease activity index (SLEDAI) was assessed. Genotyping of the IL-37 (rs3811047) polymorphism was done using real time polymerase chain reaction (PCR). A bioinformatic analysis of IL-37 was also performed. The mean ages of SLE patients were 32.82 ± 10.43 years and female: male was 195:11 (F:M 17.7:1). The SLEDAI was significantly higher in the patients with LN (7.9 ± 6.6) compared to those without (1.9 ± 1.8) (p < 0.001). The AA genotype was more frequently represented in patients with LN (21.6%) compared to those without (7.3%) (p = 0.007), and carriers of AA genotype had four times increased susceptibility to acquire LN compared to GG and GA (OR: 4.1). Likewise, the A allele was more represented in patients with LN (43%) than in those without (30%)(p = 0.004), and the carriers of the A allele had nearly two times more risk of developing LN compared to carriers of G allele (OR: 1.79).The AA genotype was associated with LN susceptibility under the recessive genetic model (p = 0.002). Regression analyses revealed that A allele is an independent risk factor of proteinuria (p < 0.001), disease activity (p < 0.001), consumed C3 (p < 0.001) and C4 (0.003). The AA genotype of the IL-37 (rs3811047) SNP contributes to the development of SLE in Egyptian patients with a doubled risk of acquiring LN in carriers of the allele A.
No takes yet. Share an insight, caveat, or question.
Nasef et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: